TEK and ovarian cancer: Table 2, Table 3 and Table 4 list Ang/Tie2 targeting agents used in clinical trials, with brief mechanisms, stage of the study, and key findings in (1) ovarian cancer, (2) breast cancer, and (3) CRC, respectively, as the main three malignancies studied for the effect of Ang/Tie2 targeting compounds.